© Candor

Many users in research labs like to store their assay components such as assay antibodies, conjugates, antigens, calibrators or coated ELISA plates for a while without losing functionality.

Three cryo-electron microscopic views of the protein complex ClpX-ClpP. © C. Gatsogiannis / MPI of Molecular Physiology

German researchers have determined the mechanism of a ADEPs, a novel class of antibiotics, allowing for pharmacological optimisation.

Christian Eggeling from Leibniz IPHT and the Friedrich Schiller University Jena © Jan-Peter Kasper/ Friedrich Schiller University Jena

A new method allows real-time-visualisation of how the HI virus spreads between living T helper cells and which molecules it requires for this purpose.

Source: EuropaBio

How can biotechnology and bioeconomy contribute to establish a sustainable and circular economy? Nearly 500 attendees discussed latest trends at EFIB 2019 in Brussels. 

Rottapharm Biotech has experience in the development of both, small molecules and therapeutic antibodies. @ Rottapharm Biotech

Rottapharm Biotech (Monza, Italy) has published detailed results from a clinical Phase II trial of CR4056 in chronic pain from knee osteoarthritis.

H.E.L. Group Ltd has a new CEO: The global manufacturer of laboratory tools for process optimisation, safety and scale-up announced the appointment of Louise Madden as Chief Executive Officer.

© asebio
Spain’s biotech association Asebio announced new record numbers from its biotech investor day held as part of the European Biotech Week.
Creoptix Wave chip combines microfluidics and sensor in a disposable cartridge. © Creoptix AG

Swiss drug discovery analytics specialist Creoptix AG has raised CHF8m in a Series C financing for commercial expansion.

 Edwin Klumper of Lytix Biopharma has stepped down from his role as CEO. The board has decided to promote Head of R&D Øystein Rekdal to the position of CEO.

Neisseria gonorrhoeae © Centers of Disease Control and Prevention (CDC)
Entasis Therapeutics Inc (Waltham, USA) and non for profit organisation GARDP (Geneva, Switzerland) have initiated Phase III testing of the novel antibiotic zoliflodacin to treat infections with the WHO priority pathogen N. gonorrhoea.